Q3 Sales Up 4.5%, EBITDA Up 6.6%, But Full-Year EBITDA Guidance Points Down 2%
GPGI sits 21% above its 52-week low of $10.43.
Summary
GPGI delivered Q3 pro forma adjusted net sales of $509.6 million, up 4.5% year over year, and pro forma adjusted EBITDA of $146.3 million, up 6.6%, with margin expanding 60 bps to 28.7%. Net income was $76.0 million, or $0.26 diluted EPS, versus a prior-year GAAP loss driven by warrant and earnout revaluations. The problem is the outlook: Q4 EBITDA guidance of $178-208 million is up 8% at the midpoint, but full-year 2026 EBITDA of $520-550 million is down 2% year over year at the midpoint, implying the first three quarters ran below the pace needed to hold 2025 levels. Management called results in line with expectations, citing record strength at CompoSecure and improving demand at Husky, and said it expects a return to its long-term growth algorithm in 2027. Note the accounting wrinkle: GAAP results show the operating businesses as equity method investments, so the adjusted and pro forma figures are the numbers that matter here. The 8:00 a.m. ET call will carry the detail on the Q4 ramp and the 2027 recovery claim.
At the time of this announcement, GPGI was trading at $12.60 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $10.43 to $26.50. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.